Baluyan, Allen John C.
HRN: 04-87-08 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/29/2022
CO-AMOXICLAV 625MG (TAB)
10/29/2022
11/05/2022
ORAL
625mg
BID
Multiple Abrassions
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes